Contact CVRx Contact CVRx

BeAT–HF pivotal trial results1

Barostim plus GDMT achieves significant and meaningful improvements for heart failure patients beyond GDMT alone

+60
Meters
greater 6MHW results with Barostim
-14
Points
improvement in QOL with Barostim
34%
Improved
improved at least 1 NYHA class at 6 months with Barostim

Significant reduction in NT-proBNP

-25%
NT-proBNP
reduction in NT-proBNP with Barostim

Safe procedure and a potential reduction in serious cardiovascular events

97%
MANCE-free rate in Barostim arm1
51%
Potential reduction in serious cardiovascular-related hospitalization events with Barostim5

1. Zile MR, et al. J Am Coll Cardiol 2020; 76:1-13;
2. Gremeaux V, et al. Arch Phys Med Rehabil. 2011;92(4):611-619.;
3. Rector TS, et al. J Card Fail. 1995;1(3):201-216.;
4. Zile MR, et al. J Am Coll Cardiol. 2016;68:2425-2436.;
5. Zile MR, et al. Am Coll Cardiol 2020; Supplemental Appendix Table 13.

BeAT-HF JACC Publication

Read the BeAT-HF JACC publication

View / Download
BeAT-HF Clinical Data Summary

Clinical data summary

View / Download
BeAT-HF Data Slides

HRS.20 BeAT-HF data slides

View / Download
More Publications

Ready to learn more about Barostim?